SIBN
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
SI-BONE, Inc. (SIBN) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (3.0) | C (2.4) | B+ (3.7) | A- (3.9) | C+ (2.6) | B- (3.1) |
| 2026-11-07 | B- (3.0) | C (2.3) | B+ (3.7) | A- (4.1) | C+ (2.7) | B- (3.1) |
| 2026-10-31 | B- (3.0) | C (2.4) | B+ (3.6) | B+ (3.7) | C+ (2.7) | B- (3.1) |
| 2026-10-24 | B- (3.0) | C (2.4) | B+ (3.6) | B+ (3.6) | C+ (2.6) | B- (3.1) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe